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Cardiovascular diseases (CVD) are a group of disorders involving the heart and its related 
blood vessels. Cardiovascular diseases  CVD is now  a common cause of global mortality 
and largely contributed to the disease-related disabilities which poses a major impact on the 
costs of treatment and healthcare in most countries.   Since the last decade,  cardiovascular 
diseases have accounted for 31% of deaths worldwide and the single largest contributor to 
the global mortality.  Leptin, has been shown to play important role in the development of 
cardiovascular diseases. However, the association of leptin and the long term outcomes of 
CVD patients is rarely being reported.  This research aimed to determine the serum leptin 
levels and lipid profiles among patients with stable coronary artery disease.  In this study, 
100 participants were recruited from the pool of patients attending the Cardiac Clinic at the 
Sarawak Heart Centre (PJS) from the year 2015 till 2016. The serum leptin levels were 
determined by using ELISA method, whereas the lipid profile level were determined by 
using the blood biochemistry analyser Beckman Coulter AU680. Results showed a positive 
correlation between lipid profile parameter and serum leptin levels in patients with stable 
coronary artery disease (CAD).  However only one parameter of the lipid profile, which is 
the triglyceride level shows positive correlation with correlation coefficient, r:0.318 and p 
value <0.005. The strength of linear relationship increased in the correlation of serum leptin 
level and triglyceride level among the non-diabetic stable CAD patients (r = 0.439, p 
<0.001). Serum leptin levels correlate well with the body mass index of the stable CAD 
patients involved in the study (<0.001).   Positive correlation between serum leptin levels 
and BMI also seen among non-diabetic groups (<0.001). Based on these findings, a combo 




to treat and manage coronary artery disease patients. Therefore, a future study is required to 
test this intervention and hopefully this can bring a new insights regarding the role of these 
biomarkers in cardiovascular disease research, testing and its clinical management. 
 



























Penyakit kardiovaskular (CVD) merupakan kumpulan penyakit yang melibatkan jantung 
dan saluran darah. Penyakit kardiovaskular merupakan penyebab utama kematian global 
dan sebahagian besarnya menyumbang kepada implikasi besar terhadap kos rawatan dan 
penjagaan kesihatan di kebanyakkan negara. Sejak sedekad lalu, kematian yang dikaitkan 
dengan penyakit kardiovaskular adalah 31% kematian di seluruh dunia dan merupakan 
penyumbang terbesar kepada kematian global. Leptin adalah protein yang memainkan 
peranan penting dalam perkembangan penyakit kardiovaskular. Walaubagaimanapun, 
pertalian antara leptin dan hasil jangka panjang penyakit kardiovascular (CVD) sangat 
jarang dilaporkan. Kajian ini bertujuan menentukan hubungan antara serum leptin dan 
profil lipid di kalangan pesakit koroni arteri stabil. Dalam kajian ini, 100 orang calon 
adalah pesakit yang hadir di klinik jantung di Pusat Jantung Sarawak (PJS) dari 2015 
hingga 2016. Serum leptin dikenalpasti menggunakan kaedah  ELISA manakala profil lipid 
di analisis secara automatik menggunakan mesin biokimia Beckman Coulter AU680. 
Keputusan menunjukkan tidak ada perbezaan yang ketara antara paras serum leptin dan 
bangsa yang berbeza (nilai-p 0.007). Walaubagaimanapun, hanya satu parameter lipid iaitu 
trigliserida menunjukkan korelasi yang positif dengan serum leptin dengan pekali korelasi 
r = 0.318 dan nilai p <0.005. Kekuatan hubungan korelasi di antara tahap serum leptin dan 
level trigliserida telah meningkat pada kumpulan pesakit koronari arteri yang stabil dan 
bukan pesakit diabetes mellitus (r = 0.439, p<0.001). Level serum leptin berkolerasi baik 
dengan index jisim badan pada pesakit koronari arteri yang stabil dalam kajian ini 




dalam kumpulan pesakit yang tiada diabetes mellitus (<0.001). Berdasarkan hasil kajian 
ini, ujian kombo yang merangkumi ubat yang merendahkan tahap lipid dan ubat yang 
merendahkan tahap leptin berkemungkinan berpotensi untuk merawat dan menguruskan 
pesakit koronari arteri. Oleh yang demikian, kajian di masa depan perlu dilakukan untuk 
menguji hasil kajian ini dan berharap ianya boleh membawa satu wawasan yang baru 
mengenai peranan biomarker ini dari segi ujian, penyelidikan dan pengurusan klinikal 
penyakit kardiovaskular.   
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Cardiovascular diseases (CVD) are a group of disorders involving the heart and its related 
blood vessels.  CVD is now  a common cause of global mortality and largely contributed to 
the disease related disabilities which poses a major impact on the costs of treatment and 
healthcare in most countries.   Since the last decade, death due to cardiovascular diseases 
accounted for 31% of deaths worldwide and CVD was the single largest contributor to global 
mortality and is expected to continue to be the major cause of mortality in the future.  Among 
16 million deaths among individuals younger than 70 years caused by non-communicable 
diseases (NCDs), 82% were in low- and middle-income countries, and 37% were caused by 
cardiovascular diseases (WHO, 2016).    
 
In Malaysia, cardiovascular diseases are the dominant cause of morbidity and mortality in 
the last ten years.  The National Health and Morbidity Surveys (NHMS) have shown that the 
prevalence of the cardiovascular (CV) risk factors which include hypertension, 
hypercholesterolemia, diabetes, overweight, obesity and smoking has been on an increasing 
trend. The National Cardiovascular Disease – Acute Coronary Syndrome (NCVD-ACS) 
Registry has also shown that Malaysians are developing heart disease at a younger age than 





Cardiovascular disease comprises of many types of conditions which include 
cerebrovascular disease, peripheral arterial disease and coronary artery disease.   Coronary 
artery disease (CAD) involves impairment of blood flow through the coronary arteries, most 
commonly by atheromas.  Coronary artery disease is the leading cause of death in both sexes, 
accounting for about one third of all deaths in developed countries.  According to the World 
Health Organization, CAD accounted for 98.9 deaths per 100,000 populations in Malaysia 
in 2012 and it is the most common cause of deaths from non-communicable diseases in the 
country (WHO, 2015).  The Malaysian burden of disease study conducted in 2000 found 
CAD to be the biggest cause of death with a total of 22,158 deaths or about one fifth of all 
deaths in the country (Yusoff et al., 2005).   Information on the burden of disease which 
were obtained from death certifications and hospital admission records in Ministry of Health 
hospitals showed that circulatory disease accounted for 6.99% of total hospital admissions 
and 23.34% of all hospital deaths in 2014. 
 
1.2 Leptin and cardiovascular diseases 
Leptin, an adipokine, has been largely implicated in the increased cardiovascular risks. This 
hormone exerts several cardiovascular actions such as platelet aggregation, sympathetic 
activation, insulin resistance and proangiogenic effect, which suggest its important role in 
the development of cardiovascular diseases (Behowski, 2006).   As the product of a 16- kDa 
obese gene found in early 1990s, leptin is primarily secreted by the white adipocytes and is 
one of the most prominent peptide that regulates appetite and energy expenditure 
(Ghalandari et al., 2015).   High level of serum leptin has been implicated in inflammatory, 
metabolic and homeostatic factors involved in obesity, hypertension and cardiovascular 




isoforms are expressed in cardiomyocytes, vascular smooth muscle cells, and endothelia 
(Heida et al., 2010).  Moreover, leptin resistance arose from hyperleptinemia was shown to 
enhance endothelial oxidative stress, stimulating the proliferation of vascular smooth muscle 
cells as well as inducing the thickening of injured arterial vascular walls, which in turn 
stimulates the formation of reactive oxygen species and activates the renin–angiotensin–
aldosterone system, leading to the imbalance between vasoconstriction and vasodilatation 
with the consequent development of CVD. 
 
1.3 Significance of study 
Generally, CVD is the result of an interaction between various genetic, sociodemographic, 
economic, individual, environmental and health delivery system-related factors.  Several 
recent studies have also reported that body mass index (BMI) is one of the strongest 
predictors of CVD (Chang & Chen, 2018).  Essentially, efforts to prevent CVD should 
address all of these factors. However, because CVD involves interactions between multiple 
factors, using a single risk factor for predicting CVD is unreliable and may cause erroneous 
outcomes. One of the most efficient approaches to determining CVD risk is by considering 
the maximum number of all probable determinants to give a better picture and 
understanding, hence providing a more efficient steps in the management of patients with 
cardiovascular diseases.  
 
Previous research has established various risk factors of CVD.   Five modifiable risk factors, 
namely abnormal lipids, hypertension, current smoking, diabetes and abdominal obesity 
were shown to contribute to about 80% of myocardial infarcts (John et al., 2011). Diet and 
lifestyle factors such as smoking, physical inactivity and alcohol consumption, may 
